Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreUtilising the extensive range of data assets exclusively available to IQVIA, combined with our market leading expertise, we are able to support the NHS meet the challenge of delivering high quality, efficient and cost effective healthcare by identifying actionable insight and realising the value in data.
Learn MoreWe believe in the UK’s potential to become a global leader in the life sciences sector, and our investments announced in the 2018 Second Life Sciences Sector Deal further support the UK Government and the industry’s aim to make that potential a reality.
Learn MoreWe are committed to providing solutions that inform and enable all stakeholders across UK healthcare, to innovate with confidence, maximise opportunities, and, ultimately, drive human health outcomes forward.
Learn MoreIQVIA’s Pharmacy Communications offers pharma companies a simple and cost-effective channel to communicate product changes, updates and patient advice directly to patients via pharmacists.
Learn MoreExplore our library of resources spanning the healthcare & life science ecosystem on the latest topics, trends, and market developments that matter to you.
Learn MoreOncology continues to be a hotbed of innovation, with over 100 new cancer treatments expected to launch in the next five years alone. This frantic activity makes oncology one of the key growth engines of the biopharmaceutical industry and underpins its status as the dominant therapy area, generating $223 billion of global sales in 2023, at ex-manufacturer prices.
However, achieving commercial success in oncology is becoming increasingly difficult. Innovators face overwhelming complexity, opportunity fragmentation and a widening ‘innovation readiness’ gap, as healthcare systems cannot keep up with the pace of oncology innovation to effectively adopt new therapies.
A panel of EMEA strategy consulting experts will discuss case study examples of how successful oncology launches have mastered three strategic pillars—healthcare system readiness, value and evidence, and stakeholder engagement.
Join us to explore the evolving oncology innovation landscape, learn how to navigate a challenging environment, and master launch excellence to fulfil the promise of ground-breaking transformational therapies.
3 key takeaways:
Dr. Stefan Lutzmayer
Senior Consultant, EMEA Thought Leadership, IQVIA
Kirstie Scott
Senior Consultant, EMEA Thought Leadership, IQVIA
Cristina Alzaga-Chaudhry
EMEA LEAD, Commercial Strategy & Transformation
Commercial Services, IQVIA
Parmender Dahiya
Associate Principal, Strategy Consulting EMEA, IQVIA